FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2040274629> ?p ?o ?g. }

• W2040274629 endingPage "210" @default.
• W2040274629 startingPage "205" @default.
• W2040274629 abstract "Negative feedback regulation of pancreatic proteases controls pancreatic secretion in most species and pancreatic growth in rodents. Its mechanism involves the inhibition of intraluminal proteases, resulting in sustained elevation of plasma cholecystokinin (CCK) concentrations, producing a chronic trophic stimulus to the pancreas that leads to the formation of pancreatic nodules and adenomas. Ximelagatran, whose active form, melagatran, inhibits both thrombin and the serine protease trypsin, is under clinical development as an oral anticoagulant. Recent data indicate species differences in the expression of CCK receptor subtypes in the pancreas. CCK1 receptors are abundant in rat pancreas but are either absent or present at very low levels in human pancreas. As part of the clinical studies, we examined whether long-term ximelagatran administration causes CCK release and exerts possible trophic effects on the pancreas in humans.One hundred thirty patients requiring anticoagulation treatment for atrial fibrillation randomly received, in a double-blind fashion, either 36 mg oral ximelagatran twice daily or warfarin dose adjusted to an international normalized ratio of 2.0 to 3.0. Before enrollment and after 12 months of treatment, computed tomography scans of the pancreas were performed, and pancreas volumes were quantified using the summation-of-areas technique. Three months after the initiation of drug treatment, plasma CCK concentrations were measured by radioimmunoassay 120 minutes after the patients drank 240 mL of a mixed liquid meal (Ensure).After 3 months of treatment, plasma CCK concentrations did not differ between the ximelagatran and warfarin groups, 15 +/- 18 and 11 +/- 17 pmol/L (X +/- SD; P = 0.22), respectively. The initial average pancreas volumes were 82 +/- 31 and 88 +/- 28 mL in the ximelagatran and warfarin groups, respectively, and decreased to 70 +/- 25 and 75 +/- 28 mL, respectively, after 12 months of treatment. Although the decrease in pancreas volume with time was significant in each group (P = 0.0001), the magnitude of the volume reduction was similar in the 2 groups.In contrast to rats, in which long-term oral administration of ximelagatran stimulates pancreatic growth and adenoma formation, in humans, ximelagatran does not increase plasma CCK concentrations and has no demonstrable trophic effect on the human pancreas." @default.
• W2040274629 created "2016-06-24" @default.
• W2040274629 creator A5005476922 @default.
• W2040274629 creator A5012282245 @default.
• W2040274629 creator A5017806292 @default.
• W2040274629 creator A5017807791 @default.
• W2040274629 creator A5030721229 @default.
• W2040274629 creator A5058874182 @default.
• W2040274629 date "2006-03-01" @default.
• W2040274629 modified "2023-10-16" @default.
• W2040274629 title "Lack of Trophic Pancreatic Effects in Humans With Long-term Administration of Ximelagatran" @default.
• W2040274629 cites W1501280734 @default.
• W2040274629 cites W1646340036 @default.
• W2040274629 cites W1672939180 @default.
• W2040274629 cites W1738640266 @default.
• W2040274629 cites W1772491977 @default.
• W2040274629 cites W1804375307 @default.
• W2040274629 cites W181365699 @default.
• W2040274629 cites W1842060488 @default.
• W2040274629 cites W1963919243 @default.
• W2040274629 cites W1976793417 @default.
• W2040274629 cites W1981160078 @default.
• W2040274629 cites W1981771634 @default.
• W2040274629 cites W2031916956 @default.
• W2040274629 cites W2040961400 @default.
• W2040274629 cites W2051244793 @default.
• W2040274629 cites W2055903954 @default.
• W2040274629 cites W2063511873 @default.
• W2040274629 cites W2063769433 @default.
• W2040274629 cites W2067802115 @default.
• W2040274629 cites W2073925618 @default.
• W2040274629 cites W2080963091 @default.
• W2040274629 cites W2084662857 @default.
• W2040274629 cites W2102352458 @default.
• W2040274629 cites W2108719148 @default.
• W2040274629 cites W2109082347 @default.
• W2040274629 cites W2111979976 @default.
• W2040274629 cites W2125994040 @default.
• W2040274629 cites W2153029682 @default.
• W2040274629 cites W2156711661 @default.
• W2040274629 cites W2329568258 @default.
• W2040274629 cites W2332036615 @default.
• W2040274629 cites W2332812403 @default.
• W2040274629 cites W2400931144 @default.
• W2040274629 cites W2418893970 @default.
• W2040274629 doi "https://doi.org/10.1097/01.mpa.0000202949.64870.87" @default.
• W2040274629 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16552342" @default.
• W2040274629 hasPublicationYear "2006" @default.
• W2040274629 type Work @default.
• W2040274629 sameAs 2040274629 @default.
• W2040274629 citedByCount "4" @default.
• W2040274629 countsByYear W20402746292018 @default.
• W2040274629 countsByYear W20402746292020 @default.
• W2040274629 crossrefType "journal-article" @default.
• W2040274629 hasAuthorship W2040274629A5005476922 @default.
• W2040274629 hasAuthorship W2040274629A5012282245 @default.
• W2040274629 hasAuthorship W2040274629A5017806292 @default.
• W2040274629 hasAuthorship W2040274629A5017807791 @default.
• W2040274629 hasAuthorship W2040274629A5030721229 @default.
• W2040274629 hasAuthorship W2040274629A5058874182 @default.
• W2040274629 hasConcept C126322002 @default.
• W2040274629 hasConcept C134018914 @default.
• W2040274629 hasConcept C170493617 @default.
• W2040274629 hasConcept C181199279 @default.
• W2040274629 hasConcept C182220744 @default.
• W2040274629 hasConcept C18903297 @default.
• W2040274629 hasConcept C2777593968 @default.
• W2040274629 hasConcept C2778764654 @default.
• W2040274629 hasConcept C49039625 @default.
• W2040274629 hasConcept C55493867 @default.
• W2040274629 hasConcept C57380142 @default.
• W2040274629 hasConcept C71924100 @default.
• W2040274629 hasConcept C72958200 @default.
• W2040274629 hasConcept C86803240 @default.
• W2040274629 hasConceptScore W2040274629C126322002 @default.
• W2040274629 hasConceptScore W2040274629C134018914 @default.
• W2040274629 hasConceptScore W2040274629C170493617 @default.
• W2040274629 hasConceptScore W2040274629C181199279 @default.
• W2040274629 hasConceptScore W2040274629C182220744 @default.
• W2040274629 hasConceptScore W2040274629C18903297 @default.
• W2040274629 hasConceptScore W2040274629C2777593968 @default.
• W2040274629 hasConceptScore W2040274629C2778764654 @default.
• W2040274629 hasConceptScore W2040274629C49039625 @default.
• W2040274629 hasConceptScore W2040274629C55493867 @default.
• W2040274629 hasConceptScore W2040274629C57380142 @default.
• W2040274629 hasConceptScore W2040274629C71924100 @default.
• W2040274629 hasConceptScore W2040274629C72958200 @default.
• W2040274629 hasConceptScore W2040274629C86803240 @default.
• W2040274629 hasIssue "2" @default.
• W2040274629 hasLocation W20402746291 @default.
• W2040274629 hasLocation W20402746292 @default.
• W2040274629 hasOpenAccess W2040274629 @default.
• W2040274629 hasPrimaryLocation W20402746291 @default.
• W2040274629 hasRelatedWork W1984190427 @default.
• W2040274629 hasRelatedWork W1991187171 @default.
• W2040274629 hasRelatedWork W2002933895 @default.
• W2040274629 hasRelatedWork W2069601051 @default.
• W2040274629 hasRelatedWork W2079790022 @default.

• next